Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Home
/
update
/
details

Biocartis Names Dr. W. Michael Korn as Chief Medical and Scientific Officer, Renowned Precision Oncology Expert

NextEdge Admin

14 Aug 2024

2 min 37 sec

Biocartis NV, an innovative molecular diagnostics company, is pleased to announce the appointment of Dr. W. Michael Korn as its Chief Medical and Scientific Officer, effective August 12, 2024.

Dr. Korn brings a wealth of experience in oncology diagnostics and precision medicine. Prior to joining Biocartis, he served as Chief Medical Officer at Invitae Corporation, where he expanded the scope of genetic testing and led the development of novel clinical studies for an advanced MRD assay. He also held the role of Chief Medical Officer at Caris Life Sciences, where he played a key role in developing AI-driven molecular signatures and advancing research in precision oncology. Additionally, Dr. Korn is a volunteer faculty member at the University of California, San Francisco (UCSF), and co-founder of the Center for Molecular Oncology Initiative at the UCSF Helen Diller Family Comprehensive Cancer Center.

Dr. Korn emphasized the importance of timely and accurate molecular information in oncology, highlighting Biocartis’ decentralized approach, which delivers critical molecular test results at the point of care in just hours. He expressed his enthusiasm for working with the Biocartis team to provide rapid, clinically relevant molecular testing to cancer patients globally.

Dr. Korn earned his medical doctorate at Philipps University Marburg and graduated from Heinrich Heine University of Düsseldorf. He completed his training in internal medicine and medical oncology at the West German Cancer Center in Essen, Germany, and is board certified in both specialties.

Roger Moody, CEO of Biocartis, expressed confidence that Dr. Korn's expertise will be instrumental in advancing Biocartis’ mission to improve cancer care through rapid molecular diagnostics.